TABLE 2.

Comparison of the efficacy of combination therapy of relatlimab and nivolumab versus nivolumab monotherapy in the treatment of melanoma with a median follow-up time of 25.3 months.

	Relatlimab and nivolumab (n = 355)	Nivolumab (n = 359)
Median PFS (95% CI)	10.2 months (6.5–14.8)	4.6 months (3.5–6.5)
Median OS (95% CI)	NR (31.5–NR)	33.2 months (25.2–45.8)
OS rate,%(95% CI)
24 months	61.8 (56.5–66.6)	58.3 (52.9–63.2)
36 months	54.1 (48.6–59.3)	48.4 (42.9–53.8)
48 months	51.5 (45.9–56.9)	42.5 (36.4–48.5)
ORR, % (95% CI)	43.7 (38.4–49.0)	33.7 (28.8–38.9)
TRAEs	61 patients (17.2%)	31 patients (8.6%)
Grades 3-4 TRAEs	78 patients (22.0%)	43 patients (12.0%)